Journal of Practical Hepatology ›› 2023, Vol. 26 ›› Issue (3): 453-456.doi: 10.3969/j.issn.1672-5069.2023.03.039
Chen Peng, Liu Huan, Xu Liang
Received:
2022-06-23
Online:
2023-05-10
Published:
2023-05-08
Chen Peng, Liu Huan, Xu Liang. Application of immune checkpoint inhibitors in treatment of patients with advanced hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2023, 26(3): 453-456.
[1] Brar G, Greten T.F, Graubard B.I, et al. Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis.Hepatol Commun, 2020, 4:1541-1551. [2] Rimassa L, Danesi R, Pressiani T, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer treat Rev, 2019,77:20-28. [3] Saffo S, Taddei TH. Systemic management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Digest Dis Sci, 2019,64 (4):1016-1029. [4] Collier JL, Weiss SA, Pauken KE, et al. Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity. Nat Immunol, 2021, 22(7):809-819. [5] Huyen PTM, Dung DTN, Weiß PJ, et al. Circulating level of sPD-1 and PD-1 genetic variants are associated with hepatitis B infection and related liver disease progression. Int J Infect Dis, 2022,115:229-236. [6] Van Coillie S, Wiernicki B, Xu J. Molecular and Cellular Functions of CTLA-4. Adv Exp Med Biol, 2020,1248:7-32. [7] Gomez S, Tabernacki T, Kobyra J, et al. Combining epigenetic and immune therapy to overcome cancer resistance. Semin Cancer Biol, 2020, 65:99-113. [8] Eso Y, Marusawa H. Novel approaches for molecular targeted therapy against hepatocellular carcinoma. Hepatol Res, 2018, 48:597-607. [9] Finkelmeier F, Waidmann O, Trojan J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther, 2018, 18(12): 1169-1175. [10] Yau T,Park J.W,Finn R.S,et al. LBA38_PR-CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs. sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann. Oncol, 2019, 30: v874-v875. [11] Lim Chiew Woon, Lee Joycelyn Jie Xin, Choo Su Pin, et al. Nivolumab for the treatment of hepatocellular carcinoma. Expert Opin Biol Ther, 2020,20(7):687-693. [12] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224):a non-randomised,open-label phase 2 trial. Lancet Oncol, 2018,19 (7):940-952. [13] Richard S Finn, Baek-Yeol Ryoo, Philippe Merle, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol, 2020,38(3):193-202. [14] Feun LG, Li YY, Wu C, et al. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. Cancer, 2019, 125(20):3603-3614. [15] Yu R, Wang W, Li T, et al. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma. Future Oncol, 2021, 17(31):4081-4089. [16] Jinzhang Chen, Xiaoyun Hu, Qi Li, et al. Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. Ann Transl Med, 2020,8(18):1187. [17] Maestri M, Pallozzi M, Santopaolo F, et al. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opin Investig Drugs, 2022,31(4):347-360. [18] Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol, 2013,59:81-88. [19] Silva IP, Long GV. Systemic therapy in advanced melanoma: Integrating targeted therapy and immunotherapy into clinical practice. Curr Opin Oncol, 2017, 29:484-492. [20] Zhou G, Sprengers D, Boor PPC, et al. Anti-bodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells inhepatocellular carcinomas. Gastroenterology, 2017,153:1107-1119.e10. [21] Thomas Yau, Yoon-Koo Kang, Tae-You Kim, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol, 2020,6(11):e204564. [22] Kevin Wright. FDA Approves Nivolumab Plus Ipilimumab for the Treatment of Advanced HCC. Oncology (Williston Park), 2020,34(4):693606. [23] Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, Vikki Tang, et al. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. J Immunother Cancer, 2021,9(2):e001945. [24] Kelley RK, Abou-Alfa GK, Bendell JC, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. J Clin Oncol, 2017,35(15_suppl):4073. [25] Kelley RK, Sangro B, Harris WP, et al. Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). J Clin Oncol, 2020, 38(suppl):4508. [26] Finn RS, Qin S, Ikeda M, et al. IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med, 2020,382(20):1894-1905. [27] Bang YJ, Golan T, Dahan L, et al. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). Eur J Cancer, 2020, 137:272-284. [28] Finn RS, Ikeda M, Zhu AX, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol, 2020, 38(26): 2970. [29] Xu J, Shen J, Gu S, et al. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Clin Cancer Res, 2021, 27(4):1003-1011. [30] Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J. Gastroenterol, 2019, 25:789-807. [31] El Dika I, Khalil DN, Abou-Alfa GK. Immune checkpoint inhibitors for hepatocellular carcinoma. Cancer, 2019, 125(19):3312-3319. [32] Ahmed Montasser, Aurélie Beaufrère, François Cauchy, et al. Transarterial chemoembolization enhances programmed death 1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology, 2021, 79(1):36-46. [33] Zheng L, Fang S, Wu F, et al. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Front Mol Biosci, 2021,7:609322. [34] Xu ZN, Huang JJ, Zhou J, et al. Efficacy and safety of anti-PD-1 monoclonal antibody in advanced hepatocellular carcinoma after TACE combined with TKI therapy. Zhonghua Nei Ke Za Zhi, 2021, 60(7):630-636. [35] Chao J, Zhu Q, Chen D, et al. Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection. Front Oncol, 2021,11:667555. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||